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CASE REPORTPityriasis lichenoides chronicaelike drug
eruption developing during pembrolizumab
treatment for metastatic melanoma
Krishna A. J. Mutgi, MD,a Mohammed Milhem, MD,b Brian L. Swick, MD,a,c and Vincent Liu, MDa,c
Iowa City, IowaFrom
Di
of
Fund
Confl
BM
Sw
Corre
Ho
OHKey words: pembrolizumab; pityriasis lichenoides chronica; programmed death receptor 1.Abbreviation used:
PD-1: Programmed death receptor 1INTRODUCTION
Immune checkpoint inhibitors such as ipilimumab
(anticytotoxic T-lymphocyteeassociated antigen),
pembrolizumab, and nivolumab (antieprogrammed
death receptor 1) represent some of the newest and
most promising medications for the treatment of
metastatic melanoma.1 As a class, immune check-
point inhibitors interferewith tumoral suppression of
T cells, resulting in a more robust immune response
and subsequent benefit in the treatment of mela-
noma, nonesmall-cell lung cancer, and potentially
other malignancies. Unfortunately, immune check-
point inhibitors also interfere with suppression of
autoimmunity, and several immune-related adverse
events have been attributed to these medications.2-4
Patients receiving programmed death receptor 1
(PD-1) inhibitors have had morbilliform eruptions,
vitiligo, pruritus, neutrophilic dermatosis, lichen
planus, psoriasis, bullous erythema multiforme,
Stevens-Johnson syndrome, and bullous pemphi-
goid.1-10 Here we present a novel case of a pityriasis
lichenoides chronicaelike drug eruption developing
during pembrolizumab therapy.REPORT OF A CASE
A 67-year-oldwomanwithmetastaticmelanoma, a
medical history of hypertension and squamous cell
carcinoma of the anus, and a family history of psori-
asis was started on pembrolizumab, 2 mg/kg every
3weeks. After her second infusion, she had dozens of
pruritic 3- to 4-mm, red-brown, thin papules with
centrally adherent micaceous scale on the forearmsthe Departments of Dermatologya; Internal Medicine,
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43205. E-mail: Krishna.Mutgi@nationwidechildrens.org.and lower legs (Fig 1,A andB). These lesions failed to
respond to over-the-counter antihistamines and
continued to worsen with each infusion. A punch
biopsywasobtained froma representative area on the
left lower leg (Fig 1, A and B).
Punchbiopsy foundaparakeratotic, spongiotic, and
focally acanthotic epidermis with exocytosis of cyto-
logically bland-appearing lymphocytes and rare neu-
trophils. Focal basal layer vacuolar degeneration with
interface and perivascular lymphocytic inflammation
and extravasated red blood cells were also observed
(Fig 2, A and B). Immunohistochemistry found an
equal ratio of CD41:CD81 cells in the epidermis and a
slight CD4 predominance in the dermis.
The combined clinical and histopathologic find-
ings were consistent with a diagnosis of pityriasis
lichenoides chronicaelike drug eruption. The skin
lesions were treated with topical clobetasol with
complete clearance within 2 months. About 1 month
after clearance of her pityriasis lichenoides
chronicaelike drug eruption an inflammatory
arthritis developed that resulted in discontinuation
of pembrolizumab and required treatment with
methotrexate. Eight months after discontinuation of
pembrolizumab, she has not had a recurrence of her
pityriasis lichenoides chronicaelike drug eruption
but is still on methotrexate for ongoing inflammatory
arthritis.JAAD Case Reports 2016;2:343-5.
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Fig 1. A and B, Pityriasis lichenoides chronicaelike drug eruption. The lower legs show
several, 3- to 4-mm, red-brown, thin papules with centrally adherent micaceous scale and
intermixed erosions.
Fig 2. A and B, Microscopic examination of stained slides of a lower leg punch biopsy found a
diffusely spongiotic epidermis with focal acanthosis dotted by exocytosis of bland-appearing
lymphocytes, extravasated red blood cells, and rare neutrophils, surfaced by overlying
parakeratosis. Focal basal layer vacuolar degeneration with interface and perivascular
lymphocytic inflammation was also observed (A and B, Hematoxylin-eosin stain; original
magnifications: A, 3100; B, 3400.)
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Immune checkpoint inhibitors have fundamen-
tally transformed the approach to the treatment of
metastatic melanoma and are already being used or
investigated as treatments for multiple other
malignancies.3 Unfortunately, as well as inducing
the immune system to eradicate malignant cells,
these medications have resulted in a variety of
immune-related adverse events. Interestingly,
although PD-1 inhibitors are thought to evoke a
primarily cytotoxic T-cell response against malignant
cells, the cutaneous immune-related adverse events
include both autoantibody (epidermolysis bullosa
acquisita and bullous pemphigoid) and psoriasiform
eruptions in addition to the more predictable
cytotoxic eruptions (morbilliform, vitiligo, lichenoid,
Stevens-Johnson syndrome and erythema multi-
forme).1-10
To our knowledge, the development of a pityriasis
lichenoides chronicaelike drug eruption during
pembrolizumab therapy has not been reported; how-
ever, a potential association may not be surprising, asboth psoriasiform and lichenoid dermatitides have
occurred during PD-1 therapy.3,4,7,9,10 In light of the
temporal relationship between starting pembrolizu-
mab and the development of a pityriasis lichenoides
chronicaelike drug eruption and the known
association of pembrolizumab with psoriasiform and
lichenoid dermatitides, we believe it is most likely that
our patient’s pityriasis lichenoides chronicaelike drug
eruptionwas induced bypembrolizumab. In our case,
the patient’s pityriasis lichenoides chronicaelike drug
eruption rapidly improved with high potency topical
steroids, allowing continuation of pembrolizumab
therapy. Subsequent development of inflammatory
arthritis, however, necessitated discontinuation
of pembrolizumab and initiation of methotrexate
therapy. Because methotrexate is also an effective
treatment for pityriasis lichenoides chronica, it is
unclear if her continued clearance is secondary to
drug discontinuation or if her pityriasis lichenoides
chronicaelike drug eruption is merely being
suppressed by methotrexate. Our case expands the
spectrum of cutaneous immune-related adverse
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Mutgi et al 345events from PD-1 inhibitors and should raise
awareness of this potentially treatable side effect of
PD-1 inhibitor therapy.
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